India  

Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod

DNA Wednesday, 16 September 2020 ()
The Drugs Controller General of India (DCGI) has allowed the Serum Institute of India (SII) to resume its phase two and three clinical trials for the Oxford-AstraZeneca COVID-19 vaccine.
0
shares
ShareTweetSavePostSend
 
Video Credit: HT Digital Content - Published
News video: Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon

Covid: 3 vaccines at clinical trial stage in India; SII’s phase 3 trial soon 01:19

Director General of the Indian Council of Medical Research (ICMR), Dr Balram Bhargava said three vaccine candidates are at different clinical trial stages in India. Covid-19 vaccine candidates being manufactured by Cadila Healthcare and Bharat Biotech have completed the first phase of the trial while...

You Might Like


💡 newsR Knowledge: Other News Mentions

Serum Institute of India Serum Institute of India Indian biotechnological company, vaccine manufacturer

Phase 3 human clinical trial of Oxford vaccine begins in Pune

The phase-III human clinical trial of the Covid-19 vaccine being developed by Oxford University, and manufactured by the Serum Institute of India (SII), began at..
IndiaTimes
Covid update: 1,500 crore vaccine doses; onion export ban; Oct-Nov warning [Video]

Covid update: 1,500 crore vaccine doses; onion export ban; Oct-Nov warning

From the CEO of the world's largest vaccine manufacturer commenting on the possible timeline of the final vaccine reaching every person on the planet, to the World Health Organisation warning that the months of October and November 2020 could be 'tougher' - here are the top news updates on the Covid-19 pandemic. Adar Poonawalla, chief executive of Serum Institute of India reportedly said that it might take 4-5 years for the vaccine to reach everyone. He estimated that around 1,500 crore vaccine doses would be required to inoculate everyone if the final vaccine is a 2-dose drug. Meanwhile, the Government of India banned the export of onions after a 30% jump in export of the kitchen staple in the April-July 2020 period. Over a dozen Members of Parliament were found to be Covid positive on the day the central legislative body convened for its monsoon session. In Delhi, the deputy Chief Minister, Manish Sisodia, tested positive on the day that the Chief Minister of neighbouring Haryana, Manohar Lal Khattar, finally recovered from the disease. Watch the full video for the other top updates on the spread of the Sars-CoV-2 coronavirus.

Credit: HT Digital Content    Duration: 02:18Published

Coronavirus disease 2019 Coronavirus disease 2019 Infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2

Tommy DeVito, Original Four Seasons Member, Dead at 92 from COVID

Tommy DeVito -- one of the original members of the iconic Doo-Wop group, The Four Seasons -- has died from coronavirus. 'Casino' actor Alfredo Nittoli confirmed..
TMZ.com
Covid: ‘50 lakh cases but almost 45 lakh recoveries’, says Health Secretary [Video]

Covid: ‘50 lakh cases but almost 45 lakh recoveries’, says Health Secretary

With India recording the highest number of COVID-19 recoveries in the world, the government on Tuesday said that for the past four consecutive days the number of daily recovered cases surpassed the new infections reported per day. Addressing a press briefing, Union Health Ministry Secretary Rajesh Bhushan said India has the highest number of recovered cases in the world at 44,97,867. "India's COVID-19 cases share is 17.7 per cent of global infections, while those who have recuperated are 19.5 per cent of total recoveries in world. The daily recoveries from COVID-19 more than number of new infections reported per day since past four consecutive days," he said.

Credit: HT Digital Content    Duration: 14:51Published

AstraZeneca British-Swedish pharmaceutical company

Opening bell: Equity indices trade higher, IT stocks shine [Video]

Opening bell: Equity indices trade higher, IT stocks shine

Equity benchmark indices traded firm during early hours on Monday on the back of positive global cues as hopes of a coronavirus vaccine were rekindled after AstraZeneca resumed its phase three trial. At 10:15 am, the BSE SandP Sensex was up by 273 points or 0.7 per cent at 39,127 while the Nifty 50 gained by 69 points or 0.6 per cent at 11,534.Except for Nifty pharma and FMCG. All sectoral indices at the National Stock Exchange were in the positive zone with Nifty IT gaining by 2.2 per cent and realty by 3.1 per cent. Among stocks, HCL Technologies spurted by 6.3 per cent to Rs 765 per share while Tech Mahindra moved up by 2.7 per cent, Tata Consultancy Services by 1.8 per cent, Infosys by 1.7 per cent and Wipro by 1.6 per cent.Realty major DLF ticked up by 2.1 per cent to Rs 157.55 per share while Oberoi Realty advanced by 4 per cent to Rs 392. The others which gained were Tata Motors, Adani Ports and HDFC.However, those which lost were Asian Paints, Bajaj Finance, Hero MotoCorp, Maruti and Bharti Infratel.

Credit: ANI    Duration: 01:04Published

For high-risk groups, government plans to fast-track vaccine

India has three vaccines in advanced stages of trial. The vaccine candidate developed by Oxford University and AstraZeneca and proposed in India by Serum..
IndiaTimes
AstraZeneca says trials of vaccine resuming [Video]

AstraZeneca says trials of vaccine resuming

AstraZeneca has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after receiving the green light from safety watchdogs, the company said on Saturday. Francis Maguire reports.

Credit: Reuters Studio    Duration: 01:07Published
AstraZeneca COVID-19 vaccine trial on hold over safety issue [Video]

AstraZeneca COVID-19 vaccine trial on hold over safety issue

A serious adverse reaction in a volunteer has triggered the safety protocol for the large-scale trial.

Credit: Al Jazeera STUDIO    Duration: 02:13Published

Drugs Controller General of India organization

COVID-19: DCGI approves CSIR's paper-based testing kit [Video]

COVID-19: DCGI approves CSIR's paper-based testing kit

Council of Scientific and Industrial Research on September 20 informed that Drugs Controller General of India has approved CSIR's paper-based testing kit called Feluda for COVID-19. CSIR, Director General S Mande said, "Our Delhi CSIR lab's been working on studying CRISPR-Cas immunity. They have experience of working in this particular area before COVID-19 and could repurpose the thing for COVID and developed a paper-based testing kit called Feluda and got formal approval from DCGA. Mande further explained the functioning of the paper based test. "It's different as RTPCR detects RNA and amplifies it using a polymerase chain reaction that is costly. This paper-based test also detects RNA but by a CRISPR guided system. The paper lights up if there is any virus RNA to show a sample is positive, in 45 minutes," he added.

Credit: ANI    Duration: 02:43Published

Serum Institute of India gets DCGI nod to resume clinical trial of Oxford Covid-19 vaccine

Drugs Controller General of India (DCGI) Dr V G Somani on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19..
IndiaTimes

Related videos from verified sources

Pakistan flies drones across LoC at night to drop AK-47s for terrorists | Oneindia News [Video]

Pakistan flies drones across LoC at night to drop AK-47s for terrorists | Oneindia News

The Jammu and Kashmir police has said that Pakistan is using drones to dump weapons like AK-47s across the Line of Control at night, revealing that Two AK assault rifles, a pistol, three AK magazines..

Credit: Oneindia     Duration: 02:33Published
Coronavirus vaccine trials still struggling for diversity [Video]

Coronavirus vaccine trials still struggling for diversity

Right now, nine COVID-19 vaccines are in or near a large-scale human trial phase. But enrollment of minorities in the trials remains a challenge.

Credit: NBC 26 Wisconsin     Duration: 02:44Published
Boris Johnson visits vaccine research lab [Video]

Boris Johnson visits vaccine research lab

Prime Minister Boris Johnson has visited a laboratory at the Jenner Institute in Oxford which is leading the research into a vaccine for Covid-19. Report by Etemadil. Like us on Facebook at..

Credit: ODN     Duration: 03:31Published

Related news from verified sources

Serum Institute of India to resume Oxford-AstraZeneca COVID-19 vaccine trials; gets DCGI nod

The Drugs Controller General of India (DCGI) has allowed the Serum Institute of India (SII) to resume its phase two and three clinical trials for the...
DNA

Serum Institute to resume COVID-19 vaccine trials in India after DCGI nod


newKerala.com

Serum Institute of India gets DCGI nod to resume clinical trial of Oxford Covid-19 vaccine

Drugs Controller General of India (DCGI) Dr V G Somani on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19...
IndiaTimes


Tweets about this